Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-004 intrathecal study in C9orf72-associated ALS or FTD
NL-OMON52278Phase 2Active, not recruiting
- Sponsor
- Wave Life Sciences
- Start
- Jun 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) comparing WVE-004 with Placebo (2 arms). Primary endpoint: Adverse events and tolerability. Started Jun 2021; status: active, not recruiting.
02
Drugs
WVE-004
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON52278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52278.